Einstein Researcher: Disputed Longevity Gene Might Still Be a Winner

Join Our Community of Science Lovers!

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American


Nir Barzilai, a prominent researcher from the Albert Einstein College of Medicine in New York, read my story today on how a group of researchers from the Rush University Medical Center in Chicago had failed to replicate an earlier result from Barzilai's team that linked a particular gene variant to protection against dementia. (The same variant had also turned up more often in extremely long-lived Ashkenazi Jews.)

The Rush study, however, found that the version of the gene in question, known as CETP I405V, might actually predispose its bearers to a higher risk of Alzheimer's.

Barzilai had been quoted in my story. But after reading it, he had more to say. His explanation reveals some of the subtleties involved in drawing associations between genes and complex mediators of health and disease. Here's a link to my original article, and Barzilai's reply is below and also at the end of my story in the comments section.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


"The validation of a single genetic variant is dependent on the genetic structure of the population. For example, Asians do not have this variant [CETP I405V], but have another CETP variant that is associated with the phenotype [of high HDLs]. In the Rush study the frequency of the VV variant [two copies of CETP I405V] was ~6 percent while it was ~20 percent in the Einstein Aging Study (Bronx) population, suggesting different genetic backgrounds (or survival). Thus, association of genotype without the phenotype is not very revealing. The question to both Rush and [our] EAS study is whether low CETP levels, high HDL levels (and large lipoprotein sizes) protect against cognitive decline? Analysis of genotypes alone may never reveal the whole truth, and geneticists need to get behind such limitations and the urge to focus on one variant at a time in a diverse populations."

Image source: Einstein Magazine

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe